Abstract
Growing prevalence of multidrug-resistant (MDR) pathogens is a major problem specifically in cases of complicated intra-abdominal infections (cIAIs) and complicated urinary tract infections (cUTIs) associated with increasing mortality, morbidity and healthcare costs leading to the need of new effective and safe treatment options. The aim of this study is to estimate the budget impact (BI) of introducing Ceftolozane/Tazobactam as treatment of cIAIs and cUTIs in public facilities under Ministry of Health Malaysia (MoHM).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
